Mybacs
Mybacs is a health and wellness company that manufactures and markets probiotic supplements designed to support digestive health, combining gut bacteria strains with vitamins, proteins, and minerals. The company products are formulated for daily use and travel, targeting digestive health, cardiac function, and overall wellbeing through scientifically selected probiotic strains. Mybacs emphasizes transparency in…
Funding snapshot
About
Mybacs is a health and wellness company that manufactures and markets probiotic supplements designed to support digestive health, combining gut bacteria strains with vitamins, proteins, and minerals. The company products are formulated for daily use and travel, targeting digestive health, cardiac function, and overall wellbeing through scientifically selected probiotic strains. Mybacs emphasizes transparency in formulation, using clinically studied bacterial strains and providing detailed information about ingredient sourcing and efficacy. The company operates a direct-to-consumer business model, offering subscription-based delivery of probiotic supplements tailored to individual health needs. Founded in 2018 and headquartered in Baar, Switzerland, Mybacs has raised approximately $5.9 million in Series A funding from investors including Global Founders Capital, naturalX Health Ventures, WENVEST Capital, and Joyance Partners.
Business model
Genomics > Applied Genomics > Consumer Genomics > Microbiomics,
Nutraceuticals Tech > Dietary Supplements > Personalized > Biochemical Testing Based
Team background
Company Wise > Boston Consulting Group
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.